Live Analyst Rating Changes 1515 upgrades, downgrades & price-target moves · freshest Wall Street data, updated daily View live feed →
Analyst Tracker/Adam Maeder
PIPR
Adam Maeder
Piper Sandler
Wall Street Analyst
★★☆☆☆
#2157
on 13Foresight · ranked by our own returns
41%
Success Rate
-5.4%
Average Return
7 of 17 calls profitable · -12.1% vs benchmark
📈 Across the calls we could measure, roughly 41% of Adam Maeder's ratings turned a profit when each position was held for 1 year — averaging -5.4% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

76 Buy 20 Hold 0 Sell
Adam's Stock Coverage 18 ratings · 2026-06-19
Company Date Position Consensus ⓘ Price Target ⓘ 1-Yr Return
ISRG
Intuitive Surgical
 Jun 02, 2026 BUY Strong Buy
+29.5% avg upside
36 analysts
$580.00
42.51% Upside
 +3.7%
ABT
Abbott Laboratories
 May 29, 2026 BUY Strong Buy
+31.2% avg upside
35 analysts
$115.00
30.09% Upside
 +3.4%
GKOS
Glaukos
 May 22, 2026 BUY Strong Buy
+5.9% avg upside
20 analysts
$165.00
26.26% Upside
 ·
STAA
Staar Surgical
 May 14, 2026 HOLD Hold
+14.3% avg upside
16 analysts
$33.00
13.37% Upside
 -10.5%
STXS
Stereotaxis
 May 13, 2026 BUY Strong Buy
+127.1% avg upside
7 analysts
$3.50
86.24% Upside
 -3.8%
NYXH
Nyxoah
 May 13, 2026 BUY Strong Buy
+857.2% avg upside
12 analysts
$7.00
337.44% Upside
 -5.2%
RXST
RxSight
 May 07, 2026 HOLD Hold
+133.2% avg upside
13 analysts
$10.00
111.50% Upside
 +3.5%
SGHT
Sight Sciences
 May 07, 2026 BUY Buy
+54.1% avg upside
13 analysts
$9.00
70.46% Upside
 -7.2%
RMD
Resmed
 May 06, 2026 HOLD Buy
+25.4% avg upside
27 analysts
$233.00
23.43% Upside
 -7.5%
EW
Edwards Lifesciences
 May 05, 2026 BUY Strong Buy
+11.7% avg upside
34 analysts
$100.00
14.41% Upside
 +4.1%
INSP
Inspire Medical Systems
 May 05, 2026 HOLD Buy
+98.0% avg upside
20 analysts
$55.00
29.16% Upside
 -12.4%
TCMD
Tactile Systems Technology
 May 05, 2026 BUY Strong Buy
+55.5% avg upside
8 analysts
$42.00
57.78% Upside
 +9.4%
STIM
Neuronetics
 Apr 07, 2026 BUY Strong Buy
+387.8% avg upside
6 analysts
$3.00
143.92% Upside
 -19.6%
LIVN
LivaNova
 Feb 19, 2026 BUY Strong Buy
+0.2% avg upside
14 analysts
$85.00
8.20% Upside
 +3.1%
RBOT
Vicarious Surgical
 Aug 13, 2025 HOLD Buy
+5297.1% avg upside
6 analysts
$7.00
2943.45% Upside
 -93.2%
NSPR
InspireMD
 Aug 01, 2025 BUY Strong Buy
+441.1% avg upside
8 analysts
$4.00
463.42% Upside
 -69.7%
NSP
Insperity
 Apr 09, 2020 BUY Buy
+36.0% avg upside
6 analysts
$74.00
104.34% Upside
 +116.9%
TSE:CNVI
Conavi Medical
 Dec 23, 2019 BUY Buy
+584.2% avg upside
4 analysts
$2.12
842.87% Upside
 ·
🔒 13 more ratings — with price targets, crowd consensus and our measured returns.
Sign in free to unlock See Pro plans
Free account unlocks every analyst's full coverage table.
Adam Maeder — Frequently Asked Questions
How accurate are Adam Maeder's stock ratings?
Based on the calls 13Foresight could measure, about 41% of Adam's ratings were profitable over a one-year hold, with an average return of -5.4% per rating, or -12.1% versus the S&P 500. We score every analyst the same way, from historical prices.
How is Adam ranked on 13Foresight?
Adam Maeder is currently ranked #2157 with a 2-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.
Which stocks does Adam cover?
Adam most recently has ratings on ISRG, ABT, GKOS, STAA, STXS, NYXH, RXST, SGHT, RMD, EW, INSP, TCMD and 6 more. See the full coverage table above for positions, price targets and our measured returns.
Where can I see other analyst ratings?
Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.